Echocardiographic GLS Monitoring Frequency During Chemotherapy
Monitor echocardiographic global longitudinal strain (GLS) every 3 months during chemotherapy, particularly during the first year of treatment for patients receiving cardiotoxic agents like anthracyclines and HER2-targeted therapies. 1, 2
Standard Monitoring Protocol
The evidence-based monitoring schedule is:
- Baseline: Before starting chemotherapy
- During treatment: Every 3 months for the first year 2
- Post-treatment: At completion, then at 6 months and 1 year 1
For patients on HER2-targeted therapies (like trastuzumab), cardiovascular assessment including GLS should occur every 3 months during the first year of treatment 2. This is a quality indicator established by the European Society of Cardiology.
Intensified Monitoring Scenarios
If cardioprotective medications are initiated (beta-blockers or ACE inhibitors/ARBs), increase monitoring frequency to monthly intervals 1. This applies when:
- EF drops below 50%
- EF decreases by >10%
- GLS shows abnormal changes (>15% relative reduction) 1
- Troponin becomes abnormal
Clinical Significance of GLS Changes
A >15% relative reduction in GLS is the critical threshold that predicts subsequent cardiotoxicity and warrants intervention 1, 3. For example, if baseline GLS is -20%, a reduction to -17% or worse (15% relative change) is significant.
Research demonstrates that GLS detects myocardial dysfunction as early as 1-3 months after treatment initiation, well before LVEF changes become apparent 4. In the intervention study by 3, GLS-guided management reduced trastuzumab discontinuation from 24% to 2.4% (p=0.009), validating the clinical utility of this monitoring approach.
Important Technical Considerations
- Temporal variability of GLS in stable patients is approximately 1.3%, with a maximum detectable difference of 3.2-3.6% 5
- Use 3 apical views (not single-view) for GLS measurement, as single-view assessments led to 15-22% disagreement in cardiotoxicity diagnosis 6
- GLS has superior reproducibility (coefficient of variance 2.9-3.7%) compared to single-chamber measurements 6
Symptom-Driven Monitoring
Beyond scheduled intervals, obtain echocardiography with GLS assessment immediately if cardiac symptoms develop at any time during or after treatment 1. Do not wait for the next scheduled assessment.
Long-Term Surveillance
For patients who complete therapy without developing cardiotoxicity, obtain post-therapy assessment and repeat echocardiography at 6 months or 1 year 1. If abnormalities persist, follow ACC/AHA heart failure guidelines for ongoing management.